ArticleBMC microbiology2025
Molecular epidemiology and genomic features of Bordetella pertussis in Tianjin, China, 2023.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPertussis, a highly contagious respiratory disease caused by Bordetella pertussis (BP), poses challenges due to genomic variation that may contribute to its persistence in vaccinated populations and the development of antimicrobial resistance.
methodsIn this study, we characterized 27 BP isolates collected from Tianjin, China in 2023, using whole-genome sequencing and multilocus genotyping (MGT) to explore their genomic diversity. For comparative analysis, we selected 165 international BP genomes to examine the genomic diversity and evolutionary traits of Tianjin strains within a global context.
resultsThe results revealed that all 27 isolates belonged to ST2 (100.0%), with no distinct phylogenetic clustering observed. Furthermore, phylogenetic analysis integrating 165 global BP genomes indicated that the Tianjin strains exhibited high genomic homogeneity with globally circulating strains. Specifically, 16 isolates (59.3%) carried the virulence genotype ptxA-1/ptxC-4/ptxP-3/prn-150(truncated)/fim2-1/fim3-1/fhaB-1, while 11 isolates (40.7%) carried the genotype ptxA-1/ptxC-4/ptxP-3/prn150/fim2-1/fim3-1/fhaB-1. Additionally, all 27 isolates exhibited complete resistance to erythromycin, azithromycin, clarithromycin, and clindamycin, whereas 18.5% of them were resistant to levofloxacin.
conclusionsThis study elucidates the phylogenetic, genomic characteristics, and drug sensitivity profiles of BP strains isolated in Tianjin, China, in 2023, providing valuable insights into BP persistence in vaccinated populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.